Join
Live feed
·
PRReleasevia Quantisnow
Ocuphire Pharma Inc. logo
Viatris Inc. logo

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

ByQuantisnow·Wall Street's wire, on your screen.
OCUP· Ocuphire Pharma Inc.VTRS· Viatris Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCUP (Ocuphire Pharma Inc.), VTRS (Viatris Inc.) and more on Quantisnow.